Skip to main content

US Makes New Alzheimer's Drug More Widely Accessible

US Makes New Alzheimer's Drug More Widely Accessible

Approximately 6.5 million Americans suffer from Alzheimer's (Representational)

The US drug regulator gave full approval to a new Alzheimer's medicine on Thursday, a move that makes it more widely available to the public through government-run health insurance for the elderly.

Leqembi, developed jointly by Japan's Eisai and Biogen of the United States, was shown in a clinical trial to modestly reduce cognitive decline among patients in the early stages of the disease.

But the study also raised concerns about side effects including brain bleeds and swelling.

Leqembi was initially granted "accelerated approval" by the Food and Drug Administration in January, which meant it was not broadly covered by the government-run Medicare program for people aged 65 and older.

Thursday's decision, which follows further study of the drug, means Medicare will now defray a large portion of treatment, initially listed by the makers at $26,500 per year.

"This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer's disease," senior FDA official Teresa Buracchio said in a statement.

Chiquita Brooks-LaSure, administrator of the agency that runs Medicare, added: "This is welcome news for the millions of people in this country and their families who are affected by this debilitating disease."

But people covered by Medicare will still need to meet 20 percent of the cost, or thousands of dollars, themselves.

Approximately 6.5 million Americans suffer from Alzheimer's, which is characterized by memory loss and declining mental acuity.

Leqembi, also known as lecanemab, is an antibody treatment that is injected into the brain every two weeks and works by reducing amyloid beta, a protein that builds into plaques and causes brain cells to die, as well as brain shrinkage.

The FDA's decision was welcomed by patient groups.

"This treatment, while not a cure, can give people in the early stages of Alzheimer's more time to maintain their independence and do the things they love," said Joanne Pike, Alzheimer's Association president and CEO.

"This gives people more months of recognizing their spouse, children and grandchildren."

Leqembi was the second Alzheimer's drug developed by Eisai and Biogen to receive approval. The first, Aduhelm, was approved in 2021 but the decision was highly controversial as the data about its efficacy was inconsistent.

In May, US drugmaker Eli Lilly announced its drug donanemab also significantly slowed cognitive decline associated with Alzheimer's, and would soon seek worldwide regulatory approval.

Alzheimer's disease accounts for 60 to 80 percent of dementia, according to the Alzheimer's Association. It progressively destroys thinking and memory, eventually robbing people of the ability to carry out the simplest of tasks.


 

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

Adblock test (Why?)



from NDTV News- Special https://ift.tt/el0ais4 https://ift.tt/5WpcaKn
via IFTTT

Comments

Popular posts from this blog

US Defense Chief Austin To Make 'Full Recovery' From Cancer: Doctors

Austin, a 70-year-old career soldier, initially underwent minor surgery to treat cancer on December 22. Washington: US Defense Secretary Lloyd Austin is likely to make a "full recovery" from prostate cancer and his prognosis is "excellent," two doctors said after he was seen at Walter Reed hospital for a follow-up appointment. Austin controversially kept US President Joe Biden in the dark about the cancer diagnosis for weeks, and did not inform either the commander-in-chief or Congress until days after he was hospitalized on January 1 for complications from his treatment. "Secretary Austin was seen today at Walter Reed National Military Medical Center for a scheduled post-prostatectomy surveillance appointment," the doctors said in a statement released by the Pentagon. "He continues to recover well and is expected to make a full recovery. Secretary Austin's prostate cancer was treated early and effectively, and his prognosis is excellent,...

Republic Day Updates: Macron Chief Guest As Delhi Hosts Parade Amid Dense Fog

Adblock test (Why?) from NDTV News- Special https://ift.tt/yqj8XDV https://ift.tt/zHpGab4 via IFTTT

North Korea Says It Tested New Strategic Cruise Missile

North Korea test-fired a new generation of strategic cruise missile on Wednesday. (Representational) Seoul: North Korea fired several cruise missiles towards the Yellow Sea on Wednesday, Seoul's military said, the latest in a series of tension-raising moves by the nuclear-armed state. Hours later, North Korea appeared to confirm the firing, saying it had carried out its first test of a new generation of strategic cruise missiles it is developing, the Pulhwasal-3-31. Pyongyang has accelerated weapons testing in the new year, including tests of what it called an "underwater nuclear weapon system" and a solid-fuelled hypersonic ballistic missile. "Our military detected several cruise missiles launched by North Korea towards the Yellow Sea at around 7:00 am today," the South Korean Joint Chiefs of Staff said in a statement. Unlike their ballistic counterparts, the testing of cruise missiles is not banned under current UN sanctions against Pyongyang. Cruise...